Certificate of Suitability to the Monographs of the European Pharmacopoeia
A certification issued by EDQM confirming that an active substance from a named manufacturing route complies with the relevant Ph. Eur. monograph. A CEP can be referenced in a marketing-authorisation application in place of a full active-substance master file, across the signatory states.
What this does not cover
stated in the document's own scope- Certifies the suitability of a Ph. Eur. monograph to control a named active substance; it does not grant a marketing authorisation for the finished medicine.
- Applies to active substances (and certain materials) covered by a Ph. Eur. monograph, not to substances with no applicable monograph.
- Attests monograph suitability for a specific manufacturing route; a different route or source requires its own certificate or revision.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
A Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is a certification issued by the EDQM confirming that an active substance, from a specifically named manufacturing route, is adequately controlled by the relevant European Pharmacopoeia monograph. A CEP holder can reference the certificate in a marketing-authorisation application in place of submitting a full active-substance dossier, so a single assessment by EDQM can be relied on by multiple applicants and multiple national authorities across the signatory states. Separate CEP types cover chemical purity, the risk of transmissible spongiform encephalopathy (TSE), and herbal substances.
Scope & applicability
API manufacturers supplying substances into Europe, and the finished-product manufacturers who reference their CEPs.
Legal basis & how it acquires force
The CEP procedure is operated by the EDQM under the Council of Europe within the framework of the Convention on the Elaboration of a European Pharmacopoeia. Its standing derives from that Convention and from EU pharmaceutical legislation, which recognises a CEP as an acceptable means of demonstrating the quality of an active substance in a marketing-authorisation application. So the CEP does not replace the marketing authorisation; it is a recognised certification that substitutes for the active-substance quality documentation the authorising bodies would otherwise assess individually.
Document structure
| Part | Covers |
|---|---|
| Chemical-purity CEP | Certifying that a Ph. Eur. monograph adequately controls the purity of an active substance from a named route |
| TSE-risk CEP | Certifying that a material meets the requirements for minimising transmissible spongiform encephalopathy risk |
| Herbal CEP | Certifying herbal substances and preparations against the applicable Ph. Eur. monograph |
| Assessment and inspection | EDQM evaluation of the submitted data, with GMP inspection of the manufacturing site where warranted |
| Lifecycle management | Revisions, renewals, and suspension or withdrawal of an issued certificate |
Key requirements
- A valid, current CEP covering the actual route and site of manufacture
- Change notification to EDQM where the certified conditions change
- Finished-product holders monitoring the status of every referenced CEP
Implementation tips
- Add CEP status verification to periodic supplier review — a withdrawn CEP is a supply interruption and a regulatory one at the same time
- Confirm the CEP covers the specific route and site your material actually comes from, not merely the supplier name
- Where no CEP exists, plan for an ASMF per market and price the difference in effort honestly
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The CEP is tied directly to the European Pharmacopoeia (Ph. Eur.): the certificate attests suitability of the specific monograph for the named substance and route. It is recognised across the Convention’s signatory states and by countries that have accepted the procedure, and it interlocks with EU GMP because EDQM can inspect the manufacturing site. It is the Ph. Eur./Council-of-Europe counterpart to the active-substance master file route used within individual dossiers.
CEP (EDQM Certification): frequently asked questions
Quick answers to common questions about CEP (EDQM Certification).
What is a CEP and who issues it?
A Certificate of Suitability to the monographs of the European Pharmacopoeia, issued by the EDQM under the Council of Europe. It confirms that a Ph. Eur. monograph adequately controls an active substance made by a specifically named manufacturing route.
What can a CEP be used for?
It can be referenced in a marketing-authorisation application in place of a full active-substance dossier, so a single EDQM assessment can be relied on by many applicants and authorities across the signatory states.
Does a CEP replace a marketing authorisation?
No. A CEP certifies the quality of an active substance against its Ph. Eur. monograph; the finished medicine still needs its own marketing authorisation from the competent authority.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.